TY - JOUR
T1 - Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients
AU - D'Argenio, David A.
AU - Wu, Manhong
AU - Hoffman, Lucas R.
AU - Kulasekara, Hemantha D.
AU - Déziel, Eric
AU - Smith, Eric E.
AU - Nguyen, Hai
AU - Ernst, Robert K.
AU - Larson Freeman, Theodore J.
AU - Spencer, David H.
AU - Brittnacher, Mitchell
AU - Hayden, Hillary S.
AU - Selgrade, Sara
AU - Klausen, Mikkel
AU - Goodlett, David R.
AU - Burns, Jane L.
AU - Ramsey, Bonnie W.
AU - Miller, Samuel I.
N1 - Funding Information:
The RIS cohort (CoRIS) is supported by the Instituto de Salud Carlos III through the Red Tem?tica de Investigaci?n Cooperativa en Sida (RD06/ 006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R!D!I and cofinanced by ISCIII-Subdirecci?n General de Evaluaci?n y el Fondo Europeo de Desarrollo Regional (FEDER). This work was supported in part by grants from Plan Nacional de I!D!I, Fondo Europeo de Desarrollo Regional-FEDER (https://www.isciii.es/QuienesSomos/ Organizacion/SGRCIC/Paginas/default.aspx) (RD16/0025/0040; RD16/ 0025/0026), and Fundacion Progreso y salud, Junta de Andalucia (http:// www. juntadeandalucia.es/fundacionprogresoysalud/es) (PI-0550- 2017).
PY - 2007/4
Y1 - 2007/4
N2 - The opportunistic pathogen Pseudomonas aeruginosa undergoes genetic change during chronic airway infection of cystic fibrosis (CF) patients. One common change is a mutation inactivating lasR, which encodes a transcriptional regulator that responds to a homoserine lactone signal to activate expression of acute virulence factors. Colonies of lasR mutants visibly accumulated the iridescent intercellular signal 4-hydroxy-2-heptylquinoline. Using this colony phenotype, we identified P. aeruginosa lasR mutants that emerged in the airway of a CF patient early during chronic infection, and during growth in the laboratory on a rich medium. The lasR loss-of-function mutations in these strains conferred a growth advantage with particular carbon and nitrogen sources, including amino acids, in part due to increased expression of the catabolic pathway regulator CbrB. This growth phenotype could contribute to selection of lasR mutants both on rich medium and within the CF airway, supporting a key role for bacterial metabolic adaptation during chronic infection. Inactivation of lasR also resulted in increased β-lactamase activity that increased tolerance to ceftazidime, a widely used β-lactam antibiotic. Loss of LasR function may represent a marker of an early stage in chronic infection of the CF airway with clinical implications for antibiotic resistance and disease progression.
AB - The opportunistic pathogen Pseudomonas aeruginosa undergoes genetic change during chronic airway infection of cystic fibrosis (CF) patients. One common change is a mutation inactivating lasR, which encodes a transcriptional regulator that responds to a homoserine lactone signal to activate expression of acute virulence factors. Colonies of lasR mutants visibly accumulated the iridescent intercellular signal 4-hydroxy-2-heptylquinoline. Using this colony phenotype, we identified P. aeruginosa lasR mutants that emerged in the airway of a CF patient early during chronic infection, and during growth in the laboratory on a rich medium. The lasR loss-of-function mutations in these strains conferred a growth advantage with particular carbon and nitrogen sources, including amino acids, in part due to increased expression of the catabolic pathway regulator CbrB. This growth phenotype could contribute to selection of lasR mutants both on rich medium and within the CF airway, supporting a key role for bacterial metabolic adaptation during chronic infection. Inactivation of lasR also resulted in increased β-lactamase activity that increased tolerance to ceftazidime, a widely used β-lactam antibiotic. Loss of LasR function may represent a marker of an early stage in chronic infection of the CF airway with clinical implications for antibiotic resistance and disease progression.
UR - http://www.scopus.com/inward/record.url?scp=34247333058&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2958.2007.05678.x
DO - 10.1111/j.1365-2958.2007.05678.x
M3 - Article
C2 - 17493132
AN - SCOPUS:34247333058
SN - 0950-382X
VL - 64
SP - 512
EP - 533
JO - Molecular Microbiology
JF - Molecular Microbiology
IS - 2
ER -